These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 9458299)

  • 1. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
    Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
    Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy.
    Massa E; Madeddu C; Lusso MR; Gramignano G; Mantovani G
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):175-82. PubMed ID: 16213740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
    Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
    Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin in the treatment of anemia of prematurity.
    Chen JY; Wu TS; Chanlai SP
    Am J Perinatol; 1995 Sep; 12(5):314-8. PubMed ID: 8540930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function.
    Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS
    Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
    Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
    J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
    Beguin Y
    Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
    Nowrousian MR
    Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy.
    Caravaca F; López-Minguez JR; Arrobas M; Cubero J; Pizarro JL; Cid MC; Sanchez-Casado E; Miranda MP
    Nephrol Dial Transplant; 1995; 10(9):1720-4. PubMed ID: 8559495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
    Holley JL; Nolan TA; Piraino B
    Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
    Abbrederis K; Bassermann F; Schuhmacher C; Voelter V; Busch R; Roethling N; Sendler A; Siewert JR; Peschel C; Lordick F
    Ann Thorac Surg; 2006 Jul; 82(1):293-7. PubMed ID: 16798232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
    Katodritou E; Terpos E; Zervas K; Speletas M; Kapetanos D; Kartsios C; Verrou E; Banti A; Effraimidou S; Christakis J
    Ann Hematol; 2007 May; 86(5):369-76. PubMed ID: 17375302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
    Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
    Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.
    Case DC; Bukowski RM; Carey RW; Fishkin EH; Henry DH; Jacobson RJ; Jones SE; Keller AM; Kugler JW; Nichols CR
    J Natl Cancer Inst; 1993 May; 85(10):801-6. PubMed ID: 8487324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.